Among the secondary objectives, it was possible to evaluate the impact of the oral EGFR/HER2 inhibitor on the signaling pathways of the receptors and downstream in the tumor tissue, as well as the correlations between the response and the inhibition of downstream signaling. This evidence concerns the gene ERBB2 and neoplasm.